Star Therapeutics, a late clinical-stage biotechnology company focused on the discovery and development of life-changing therapies for diseases with significant unmet need, today announced an upcoming ...
Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year. 2025 was a slow year for IPOs, with ...
Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-track ...
Parabilis Medicines CEO Mathai Mammen, M.D., Ph.D., told Fierce the industry had been in “retreat mode for some time” before its latest rebound. (mesh cube/iStock/Getty Images Plus) Elon Musk's SpaceX ...
In its annual Biotech Beyond Borders report, EY projects growth to continue throughout 2026, fueled primarily by the increased volume and value of M&A and licensing deals. (Techa Tungateja/GettyImages ...
So far in 2026, biotech deals amounted to $106 billion over 201 transactions, according to PitchBook data. That momentum in dealmaking comes despite an interest rate environment that has turned for ...
As the Treasury Department works to finalize the rules under the COINS Act, the biotech industry is locked in a fierce debate over whether choking off Chinese partnerships genuinely safeguards ...
Forbes contributors publish independent expert analyses and insights. I cover lifestyle, art, and interior design. This voice experience is generated by AI. Learn more. This voice experience is ...
Garde, who has covered biotech for nearly 15 years, spoke with more than a dozen investors, entrepreneurs, and industry leaders about how China has caused a rift between peers and partners. Damian ...
Kosloff is a co-chair of a working group with the China Strategy Initiative at the Council on Foreign Relations and a senior fellow at American Economic Liberties Project. China’s rise is happening ...
The American Biotech Innovation Alliance launches to unify domestic strategy amid global competition
Rather than compete with other advocacy groups like BIO, PhRMA and the newly formed Midsize Biotech Alliance of America (MBAA), ABIA says it aims to complement their efforts by focusing on areas of ...
The next chapter of the Event Horizon saga is officially unfolding in the comics. After the massive success of the prequel miniseries Event Horizon: Dark Descent, IDW has dropped a sequel set 200 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results